Mainz Biomed BV logo

Mainz Biomed BVNASDAQ: MYNZ

Profile

Sector:

Healthcare

Country:

Germany

IPO:

05 November 2021

Next earnings report:

22 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.37 M
-98%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-102%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 8 min ago
$0.21-$0.01(-3.58%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

MYNZ Latest News

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
globenewswire.com21 October 2024 Sentiment: POSITIVE

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
globenewswire.com01 October 2024 Sentiment: POSITIVE

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
globenewswire.com18 September 2024 Sentiment: POSITIVE

BERKELEY, Calif. and MAINZ, Germany, Sept.

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
globenewswire.com25 July 2024 Sentiment: POSITIVE

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Provides Half Year 2024 Corporate Update
globenewswire.com02 July 2024 Sentiment: POSITIVE

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
globenewswire.com03 June 2024 Sentiment: POSITIVE

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed's mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
globenewswire.com28 May 2024 Sentiment: POSITIVE

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm BERKELEY, Calif. and MAINZ, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
globenewswire.com20 May 2024 Sentiment: POSITIVE

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company's mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer prevention BERKELEY, Calif. and MAINZ, Germany, May 20, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
Zacks Investment Research08 March 2024 Sentiment: POSITIVE

Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
GlobeNewsWire29 November 2023 Sentiment: POSITIVE

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

What type of business is Mainz Biomed BV?

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.

What sector is Mainz Biomed BV in?

Mainz Biomed BV is in the Healthcare sector

What industry is Mainz Biomed BV in?

Mainz Biomed BV is in the Diagnostics & Research industry

What country is Mainz Biomed BV from?

Mainz Biomed BV is headquartered in Germany

When did Mainz Biomed BV go public?

Mainz Biomed BV initial public offering (IPO) was on 05 November 2021

What is Mainz Biomed BV website?

https://mainzbiomed.com

Is Mainz Biomed BV in the S&P 500?

No, Mainz Biomed BV is not included in the S&P 500 index

Is Mainz Biomed BV in the NASDAQ 100?

No, Mainz Biomed BV is not included in the NASDAQ 100 index

Is Mainz Biomed BV in the Dow Jones?

No, Mainz Biomed BV is not included in the Dow Jones index

When was Mainz Biomed BV the previous earnings report?

No data

When does Mainz Biomed BV earnings report?

The next expected earnings date for Mainz Biomed BV is 22 November 2024